Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Kraig Biocraft Laboratories (OTCQB: KBLB) began processing nearly 1.8 metric tons of recombinant spider silk cocoons into finished reeled silk, a production record after exceeding 1.3 metric tons in March.
The reeling is underway with a production partner and is expected to finish by month-end, creating the company's largest-ever inventory for luxury, performance textile, and industrial uses.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced senior management is traveling to South East Asia following a record monthly production of 1.3 metric tons of recombinant spider silk cocoons on April 13, 2026. The trip will review production quality, oversee downstream reeled-silk processing, and coordinate expansion with Prodigy Silk and the production network.
The company reiterated its near-term roadmap to scale toward a 10 metric ton monthly production target and highlighted leadership coverage in National Geographic.
Kraig Biocraft Laboratories (OTCQB: KBLB) produced over 1.3 metric tons of recombinant spider silk cocoons in a single month on April 6, 2026, a fivefold increase over its prior record. The company says this validates its scale-up strategy and advances its plan to reach 10 metric tons per month within coming months.
Expanded facilities, new BAM-1 Alpha production hybrids, and vertically integrated operations reportedly enabled the ramp without operational disruptions.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced the deployment of more than 700,000 BAM-1 Alpha production hybrids from a previously reported 1,000,000 egg inventory on March 30, 2026. The silkworms are now in active production as part of an aggressive, milestone-driven scale-up plan aimed at reaching metric ton output levels.
Management says the BAM-1 Alpha hybrids are exceeding internal expectations for robustness and productivity, and the Company reports this release as a key execution milestone toward industrial-scale recombinant spider silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB) expanded its R&D capacity for Project Atlas on March 23, 2026, roughly tripling screening throughput and adding staff and advanced equipment.
The upgrades automate testing workflows, strengthen analytical assays, increase parallel transgenic line evaluation, and aim to shorten development timelines and accelerate selection of production candidates.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced that Project Atlas, its next-generation bioengineering program, has passed a critical milestone and is advancing to the next phase. The program produced multiple new transgenic lines and aims to create novel spider-silk-based materials for industrial and defense uses.
The company noted Project Atlas merges multiple genetic elements into an integrated architecture to deliver enhanced strength, toughness, and other performance properties.
Kraig Biocraft Laboratories (OTCQB: KBLB) is featured on the cover of National Geographic March 2026 for its recombinant spider silk made in genetically enhanced silkworms. The piece highlights cost-efficiency, high quality, and commercialization progress, including demonstrations towing a car and suspending a person on a 0.35-ounce loop.
The company hosted the editorial team for three days of interviews and facility tours and said production operations are set to scale.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced on Feb. 17, 2026 that it has activated the first wave of its 2026 production program and moved bio-material into incubation ahead of a planned March 2026 production run. The company says it has initiated a multi-ton spider silk scale-up and expanded its manufacturing pipeline to pursue sustained monthly metric-ton-level production.
The initiative is described as the first major deployment under the 2026 roadmap, focused on execution, quality control, supply chain stability, and downstream processing capacity.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced a 2026 production plan to reach 10 metric tons of recombinant spider silk cocoon per month at full capacity by May 2026. Release of proprietary silkworm eggs begins the first week of March, with large-scale deployment starting within 30 days.
The company cites engineered production strains, expanded facilities, and workforce growth to support sustained industrial-scale output and plans for additional capacity later in 2026.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced on January 20, 2026 that it has completed construction of its most advanced spider silk gene constructs and has begun active execution of a large-scale silkworm gene-engineering program. The initiative aims to substantially increase fiber strength and elasticity, expand production scalability, and advance commercial-scale recombinant spider silk manufacturing.
The company describes the program as its most ambitious genetic engineering effort to date and says it builds on years of proprietary research.